Cargando…

Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer

Ras-targeted therapy represents a ‘holy grail’ in oncology. Based on our model prediction, Spiclomazine freezing the intermediate conformation of activated Ras is central to cancer therapeutics. We show here that Spiclomazine leads to an effective suppression in Ras-mediated signaling through abroga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xiaoyu, Zhao, Wenjing, Liu, Zuojia, Wang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805527/ https://www.ncbi.nlm.nih.gov/pubmed/29467941 http://dx.doi.org/10.18632/oncotarget.24025

Ejemplares similares

Spiclomazine Induces Apoptosis Associated with the Suppression of Cell Viability, Migration and Invasion in Pancreatic Carcinoma Cells
por: Zhao, Wenjing, et al.
Publicado: (2013)

Small Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK Signaling
por: Guo, Na, et al.
Publicado: (2016)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

KRAS mutant–driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer
por: Luo, Yuming, et al.
Publicado: (2022)

Thioredoxin system-mediated regulation of mutant Kras associated pancreatic neoplasia and cancer
por: Schultz, Michelle A., et al.
Publicado: (2017)

A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth
por: Pan, Ting, et al.
Publicado: (2016)

Targeting KRAS in PDAC: A New Way to Cure It?
por: He, Qianyu, et al.
Publicado: (2022)

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
por: Zhang, Xiaofei, et al.
Publicado: (2022)

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
por: Nollmann, Friederike Inga, et al.
Publicado: (2020)

PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
por: Ni, Qian‐Zhi, et al.
Publicado: (2022)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
por: Zeitouni, Daniel, et al.
Publicado: (2016)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth
por: Nagdas, Sarbajeet, et al.
Publicado: (2019)

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
por: Wang, Yanxiao, et al.
Publicado: (2017)

Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells
por: Hara, Toshifumi, et al.
Publicado: (2014)

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019)

Twists and turns in Kras-driven tumor initiation
por: Maru, Yoshiaki, et al.
Publicado: (2021)

Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis
por: Best, Sarah A., et al.
Publicado: (2020)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Aryl hydrocarbon receptor knockout accelerates PanIN formation and fibro-inflammation in a mutant Kras-driven pancreatic cancer model
por: Walcheck, Morgan T., et al.
Publicado: (2023)

Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8
por: Wang, Hao-Chen, et al.
Publicado: (2019)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ
por: Liu, Yi, et al.
Publicado: (2022)

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
por: Hashimoto, Ari, et al.
Publicado: (2021)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
por: Vakana, Eliza, et al.
Publicado: (2016)

A Potent Lead Induces Apoptosis in Pancreatic Cancer Cells
por: Liu, Zuojia, et al.
Publicado: (2012)

Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression
por: Jiang, Wang, et al.
Publicado: (2020)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

Brown Tumors Belong to the Spectrum of KRAS-driven Neoplasms
por: Turek, Daniel, et al.
Publicado: (2022)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Integrated multi-omics characterization of KRAS mutant colorectal cancer
por: Chong, Wei, et al.
Publicado: (2022)

Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
por: Suzuki, Tatsunori, et al.
Publicado: (2021)

Target-Specific Nanoparticle Polyplex Down-Regulates Mutant Kras to Prevent Pancreatic Carcinogenesis and Halt Tumor Progression
por: Smith, Jill P., et al.
Publicado: (2023)

Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy
por: Dai, Xin, et al.
Publicado: (2015)

A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma
por: Fitzgerald, Brittany, et al.
Publicado: (2021)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_81smrp7aap36enmvluq68d5ie4